muraglitazar

Muraglitazar is an investigational drug that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist. It was designed to activate both PPAR-alpha and PPAR-gamma receptors. Activation of PPAR-alpha is associated with effects on lipid metabolism, while activation of PPAR-gamma is linked to improved insulin sensitivity.

The drug was explored for the treatment of type 2 diabetes mellitus and dyslipidemia, conditions often occurring together in metabolic syndrome. By targeting both PPAR subtypes, muraglitazar aimed to simultaneously address elevated blood glucose levels and abnormal lipid profiles. Clinical trials were conducted to assess its efficacy and safety in patients with type 2 diabetes.

However, development of muraglitazar was discontinued. This decision was primarily due to safety concerns that emerged during clinical testing. Specifically, studies indicated an increased risk of cardiovascular events in patients treated with muraglitazar compared to placebo. The potential for adverse cardiovascular outcomes, coupled with other observed side effects, led to the cessation of its further development and regulatory review. Consequently, muraglitazar is not available for clinical use.